Press Releases.
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
November 03, 2015- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients
-
October 05, 2015RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development
-
October 02, 2015-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-
-
August 04, 2015-Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-
-
June 04, 2015-Achieves Key 'Clinical Map Initiative' Goal for 2015 and Advances Orphan Disease Efforts-
-
June 01, 2015- Paul Grint, M.D. Appointed as President and Chief Executive Officer and as a Member of the Board of Directors-
-
May 07, 2015- Advanced 'Clinical Map Initiative' with Positive Results on RG-101 and Selection of RG-125 as 3rd Clinical Candidate -
-
April 25, 2015-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-
-
April 09, 2015-Late-breaking data featured in oral presentation; three additional posters examining RG-101 pharmacokinetics, preclinical results to be presented-
-
April 07, 2015-Regulus Earns $2.5 Million Milestone Payment from AstraZeneca-
-
February 18, 2015- Achieved Key 2014 'Clinical Map Initiative' Goals to Advance microRNA Therapeutics Pipeline -
-
February 09, 2015-Extended Follow-Up Shows 4/14 Patients Treated with a Single SC Dose of 2 mg/kg of RG-101 are Target Not Detected at Day 85 -